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Antimicrobial activityAbstract With the aim of producing new biologically active compounds, a series of New Pyridine
Imidazo [2,1b]-1,3,4-thiadiazole derivatives 4(a–k) were synthesized. All the compounds were char-
acterized via IR, 1H-NMR and Mass spectral studies. The antimicrobial activity of newly synthe-
sized compounds against various bacteria; Bacillus pumillus, Staphylococcus aureus, Vibrio
cholera, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, and fungi; Candida albicans
were evaluated. Among the compounds tested, 4(a), 4(b), 4(f), 4(h) and 4(k) exhibited good antimi-
crobial activity while others responded moderately with reference to standard drugs ampicillin and
amphotericin B.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The rising prevalence of multi-drug resistant Gram positive
and Gram negative bacteria continues to provide impetus for
the search and discovery of novel antimicrobial agents activeagainst these pathogens. A large number of substituted pyri-
dines (Kallanagouda and shankar, 2011; Mohamed and Eman
2009; Massimo et al., 2000) and Imidazo [2,1-b]-1,3,4-thiadia-
zole have been claimed by researchers all around the world be-
cause of its versatile and eminent biological proﬁle. Imidazo
[2,1-b]-1,3,4-thiadiazole are known for cardiotonic (Andreani
et al., 1996), diuretic (Andreani et al., 1987), antitubercular
(Kolavi et al., 2006), anticonvulsant, analgesic (Khazi et al.,
1996), and antisecretory (Andreani et al., 2000) activities.
Moreover, interest of many medicinal chemist has also been
focused on the antibacterial (Talath and Gadad, 2006), anti-
cancer (Jadhav et al., 2008), antifungal (Guzeldemirci and
Kucukbasmaci 2010), anti-inﬂammatory (Rostom et al.,
2009), and herbicidal (Andreani et al., 1991) activities dis-
played by compounds adjoining this heterocyclic system.
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(Ghate et al., 2003) rings have been found to exhibit
antimicrobial potential, psychotropic and anti-inﬂammatory
activities and also heterocycles containing 1,3,4-thiadiazole
are well known examples for antimicrobial biological proﬁle
(Lamani et al., 2009; Padmavathi et al., 2009; Padmavathi
et al., 2008).
Over the past decade, drug resistance has become a growing
problem in the treatment of infectious disease caused by bacte-
ria, fungi and viruses. In particular, resistance of bacterial
pathogens to current antibiotic has emerged as a measure
health problem. It has been observed that these active pharma-
cophores, if linked together would generate novel molecular
templates which are likely to exhibit interesting biological
properties in animal models. The above cited applications
prompted us to synthesize a series of new compounds which
are reported in the present study.2. Results and discussion
The formation of 5,50-pyridine-2,5-diylbis-(1,3,4-thiadiazol-2-
amine) (3) by the reaction of pyridine-2,5-dicarboxylic acid
and thiosemicarbazide was conﬁrmed by IR and 1H NMR
spectral data. The spectral data of synthesized compounds
were found in full agreement with the proposed structural
compounds. IR spectrum showed the presence of amino band
at 3427 cm1 (NH2) and the absence of carbonyl group of car-
boxylic acid 1700–1600 in compound (3) therefore conﬁrm-
ing the cyclization of attached thiosemicarbazide moiety and
formation of compound (3). Moreover 1H-NMR spectrum
of compound (3) exhibited two sharp singlets at d  10.11 ppm
and d  9.90 ppm (NH2) integrating each for 2 protons,
respectively. Addition of substituted phenacyl bromide to
compound 3 in the presence of ethanol under reﬂux condition
obtained with ﬁnal derivatives as 4(a–k). Establishment of
structures of imidazo-thiadiazole derivatives 4(a–k) was car-
ried out by the absence of (NH2) band 3200 in IR spectrum
and appearance of imidazole proton in the 1H NMR spectrum.
The mass spectra of these compounds further conﬁrmed the
assigned structure.
The synthesized ﬁnal derivatives of imidazo-thiadiazole
showed potential proﬁle against various microbes. Among
the synthesized compounds 4(a), 4(b), 4(f), 4(h) and 4(k)
showed good antimicrobial activity against all strains. Out of
these compounds, 4(a) showed maximum activity against B.
pumillus (95.1%), P. aeruginosa (94.6%), V. cholera (91.0%),
S. aureus (88.8%), and P. mirabilis (87.8%) when compared
with the standard drug ampicillin. Compound 4(h) showed
maximum inhibition against S. aureus (92.0%) in comparison
to other synthesized compounds and also showed good inhibi-
tion against C. albicans (84.7%). Compound 4(f) was found to
be most active against E. coli and P. mirabilis and showed
(93.2% and 90.7%) inhibition respectively. Compound 4(f)
showed maximum activity against C. albicans (87.8%). Com-
pounds 4(b) and 4(k) showed good activity against B. pumillus
(85.2%), P. mirabilis (83.5%), S. aureus (82.7%), C. albicans
(79.9%) and V. cholera (90.1%), P. aeruginosa (82.1%) and
B. pumillus (81.7%), respectively. Apart from these com-
pounds rest all showed moderate as well some showed good
antimicrobial activity. Compound 4(a) was found to be the
most promising derivative of imidazo-thiadiazole as antibacte-rial and compound 4(f) was the most active against fungi strain
C. albicans with 87.8% inhibition. The results are reported as
shown in Table 1.
3. Experimental
All chemicals and solvents were supplied by Merck, Aldrich,
S.D. Fine Chemical Limited, Mumbai. All the solvents were
distilled and dried before use. The reactions were monitored
with the help of thin-layer chromatography using pre-coated
aluminum sheets with GF254 silica gel, 0.2 mm layer thickness
(E. Merck) and solvent systems of (5:4:1); Toulene–Ethylace-
tate–Formic acid, (9:1); benzene-acetone. Melting points of
the synthesized compounds were recorded on the Veego
(VMP-MP) melting point apparatus. IR spectrum was ac-
quired on a Shimadzu Infra Red Spectrometer, (model
FTIR-8400S). 1H NMR (DMSO) spectra of the synthesized
compounds were performed with Bruker Avance-II 400
NMR Spectrometer operating at 400 MHz in SAIF, Panjab
University (Chandigarh). Chemical shifts are reported in parts
per million (ppm) using tetramethylsilane as an internal stan-
dard. Mass spectra of the synthesized compounds were re-
corded at MAT 120 in SAIF, Panjab University.
3.1. Chemistry
The route of synthesis of compound 4(a–k) is outlined in
(scheme 1). 5,50-pyridine-2,5-diylbis(1,3,4-thiadiazol-2-amine)
(3) was prepared by reﬂuxing and cyclization of Pyridine-2,5-
dicarboxylic acid (1) treating with thiosemicarbazide (2) in the
presence of phosphorous oxytrichloride. Using appropriate
substituted phenacyl bromides under reﬂux condition in ethanol
solvent, 2,20-pyridine-2,5-diylbis [6-(substituted phenyl) imi-
dazo [2,1-b]-1,3,4-thiadiazole] 4(a–k) were obtained as ﬁnal
products. It is well established that this reaction proceeds via
the intermediate iminothiadiazole, which undergoes dehydro-
cyclization to form the desired product (Noolvi et al., 2011).
The electronic and steric factors at 5th position of 2-amino-5-
substituted-1,3,4-thiadiazole are crucial in determining the
course of its reaction. Thus the alkylation of this thiadiazole oc-
curs at 3rd nitrogen with a subsequent ring closer to form the
corresponding bridgehead nitrogen heterocyclic system. The
yield was found to be in a range of 46%–70%. The synthesized
compounds were recrystallized in appropriate solvent system
and evaluated physically.
3.2. Pharmacology: Antimicrobial activity
The synthesized compounds 4(a–k) were screened for their
antimicrobial activity using cup-plate agar diffusion method.
Both bacterial culture of B. pumillus, S. aureus, V. cholera, E.
coli, P. mirabilis, and P. aeruginosa, in nutrient agar medium
and fungal culture of C. albicans in sabouraund’s dextrose
agar medium were utilized for the study (Holla et al.,
2002). Compounds 4(a–k) tested for antibacterial activity uti-
lizing culture of B. pumillus, S. aureus, V. cholera, E. coli, P.
mirabilis, and P. aeruginosa were compared with positive con-
trol, the standard drug Ampicillin (50 lg/mL) and for anti-
fungal activity utilizing culture of C. albicans against the
standard drug amphotericin B (50 lg/mL) moreover with
negative control, the DMSO poured disk. DMSO was used
Table 1 Antimicrobial Activity data for synthesized compounds 4(a-k).
Compounds % Inhibition
B. pumillus S. aureus V. cholera E. coli P. mirabilis P. aeruginosa C. albicans
4(a) 95.1 88.8 91.0 73.5 87.8 94.6 79.2
4(b) 85.2 82.7 75.1 79.4 83.5 66.5 79.9
4(c) – – 43.5 71.2 – 32.8 66.1
4(d) 48.6 – 59.7 37.2 63.2 70.5 58.9
4(e) 23.7 – 61.5 72.6 80.3 – –
4(f) 92.0 89.9 81.6 93.5 90.7 72.0 87.8
4(g) 72.1 75.3 48.9 50.8 67.6 56.5 49.3
4(h) 89.9 92.0 88.3 90.1 79.2 86.4 84.7
4(i) – 72.2 63.0 – 57.5 73.2 65.2
4(j) 75.0 53.1 – 51.1 72.3 53.1 49.7
4(k) 81.7 79.8 90.1 72.5 77.6 82.1 70.1
Standard 100 100 100 100 100 100 100
(–) No zone of inhibition
Standard: Ampicillin for bacteria and Amphotericin B for fungi
Scheme 1 Synthesis of compounds 4(a-k); (a) Phosphorous oxytrichloride, H2O, reﬂux (b) Substituted phenacylbromide, ethanol, reﬂux.
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poured sterilized agar medium was allowed to solidify in pet-
ri-dishes. All the synthesized compounds (50 lg/mL) were
placed in sequence in the cavities with the help of micropi-
pette and allowed to diffuse for 1 h. For the antibacterial
and antifungal activities, all the plates were incubated at
37 C for 24 h and 28 C for 48 h, respectively. The zone of
inhibition was observed around the cup after respective incu-
bation and following which the zone of inhibition was mea-
sured, and % inhibition was calculated to compare the
potency of test with that of standard.3.3. Spectral characterization
3.3.1. Synthesis of 5,50-pyridine-2,5-diylbis(1,3,4-thiadiazol-2-
amine) (3)
Pyridine-2,5-dicarboxylic acid (1) (0.1 M) was reﬂuxed with
thiosemicarbazide (2) (0.2 M) and phosphorous oxytrichloride
(5 mL) for 2 h. After 2 h the mixture was cooled and diluted
with water (10 mL) and again reﬂuxed for additional 4 h. Then
the mixture was ﬁltered and ﬁltrate was neutralized with potas-
sium hydroxide solution. The precipitate was ﬁltered off and
recrystallized from ethanol.
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3427, 2924, 1414, 1349, 710; 1HNMR (DMSOd6) d ppm: 8.02
(s, 1H of pyridine), 8.50 (s, 1H of pyridine), 8.85 (s, 1H of pyr-
idine), 9.90 (s, 2H, NH2), 10.11 (s, 2H, NH2); MS (m/z%):
277.32 [M+].
3.3.2. General procedure for synthesis of 2,20-pyridine-2,5-
diylbis[6-(substituted phenyl) imidazo [2,1-b]-1, 3, 4-
thiadiazole] 4(a–k)
A mixture of 5,50-pyridine-2,5-diylbis (1,3,4-thiadiazol-2-
amine) (3) (0.01 mol) and substituted bromoacetyl compound
(a–k) (0.02 mol) was reﬂuxed in dry ethanol for 18 h. The ex-
cess of solvent was distilled off and separated solid hydrobro-
mide was collected by ﬁltration, suspended in water and
neutralized by aqueous sodium carbonate solution to get free
base. It was ﬁltered, washed with water, dried and recrystal-
lized from ethanol.
3.3.2.1. 2,20-pyridine-2,5-diylbis[6-(2, 4-dihydroxyphenyl) imi-
dazo [2,1-b]-1, 3, 4-thiadiazole] 4(a). Yellowish solid; yield
60%; mp: 320–322 C; IR (KBr, cm1): 3501, 3422, 2873,
1650, 1238, 730; 1HNMR (DMSOd6) d ppm: 10.52 (s, 2H,
OH), 10.10 (s, 2H, OH), 7.10–8.78 (m, 9H, Ar-H), 6.81 (s,
2H, Ar-H); MS (m/z%) C25H15N7O4S2: 542.57 [M+ 1]
+.
3.3.2.2. 2,20-pyridine-2,5-diylbis[6-(2-hydroxyphenyl) imidazo
[2,1-b]-1, 3, 4-thiadiazole] 4(b). Yellow solid crystal; yield
54%; mp: 282–284 C; IR (KBr, cm1): 3420, 2888, 1664,
1267, 711; 1HNMR (DMSOd6) d ppm: 10.61 (s, 1H, OH),
10.04 (s, 1H, OH), 7.13–8.92 (m, 13H, Ar-H); MS (m/z%)
C25H15N7O2S2: 509.57 [M
+]
3.3.2.3. 2,20-pyridine-2,5-diylbis[6-(3-chlorophenyl)imidazo
[2,1-b]-1,3,4-thiadiazole] 4(c). Brown solid; yield 62%; mp:
324–326 C; IR (KBr, cm1): 2925, 1643, 1402, 715, 691;
1HNMR (DMSOd6) d ppm: 8.93 (s, 2H, pyridine), 8.80 (s,
1H, pyridine), 8.69–7.31 (m, 10H, Ar-H); MS (m/z%)
C25H13Cl2N7S2: 546.48 [M
+].
3.3.2.4. 2,20-pyridine-2,5-diylbis[6-(4-chlorophenyl) imidazo
[2,1-b]-1,3,4-thiadiazole] 4(d). Light brown solid; yield
69%; mp: 336–338 C; IR (KBr, cm1): 2899, 1662, 1440,
727, 700; 1HNMR (DMSOd6) d ppm: 9.12 (s, 2H of pyridine),
8.89 (s, 1H of pyridine), 8.79–7.21 (m, 10H, Ar-H); MS (m/z%)
C25H13Cl2N7S2: 546.48 [M
+].
3.3.2.5. 2,20-pyridine-2,5-diylbis[6-(4-ﬂorophenyl) imidazo
[2,1-b]-1,3,4-thiadiazole] 4(e). White solid; yield 52%; mp:
312–314 C; IR (KBr, cm1): 2936, 1657, 1451, 681, 1017;
1HNMR (DMSOd6) d ppm: 9.31 (s, 1H of pyridine), 8.97 (s,
2H of pyridine), 8.81–7.42 (m, 10H, Ar-H); MS (m/z%)
C25H13F2N7S2: 514.55 [M + 1]
+.3.3.2.6. 2,20-pyridine-2,5-diylbis[6-(4-methylphenyl) imi-
dazo[2,1-b]-1,3,4-thiadiazole] 4(f). Brown solid; yield 57%;
mp: 306–308 C; IR (KBr, cm1): 2997, 1671, 1460, 714;
1HNMR (DMSOd6) d ppm: 9.25 (s, 1H of pyridine), 9.11 (s,
1H of pyridine), 8.94 (s, 1H of pyridine), 8.83–8.21 (m, 5H,
Ar-H), 8.01–7.54 (m, 5H, Ar-H), 2.60 (s, 6H, CH3); MS (m/
z%) C27H19N7S2: 505.70 [M
+].3.3.2.7. 2,20-pyridine-2,5-diylbis[6-(4-bromophenyl) imidazo
[2,1-b]-1,3,4-thiadiazole] 4(g). Dark brown solid; yield
61%; mp: 316–318 C; IR (KBr, cm1): 2960, 1658, 1449,
723, 675; 1HNMR (DMSOd6) d ppm: 9.16 (bs, 3H of pyri-
dine), 8.76–8.28 (m, 7H, Ar-H), 8.11 (s, 2H, Ar-H), 7.60 (s,
1H, Ar-H); MS (m/z%) C25H13Br2N7S2: 635.46 [M
+].3.3.2.8. 2,20-pyridine-2,5-diylbis[6-(4-nitrophenyl) imidazo
[2,1-b]-1,3,4-thiadiazole] 4(h). Orange solid crystals; yield
70%; mp: 324–326 C; IR (KBr, cm1): 2924, 2216, 1625,
1510, 1047, 784; 1HNMR (DMSOd6) d ppm: 9.17 (bs, 3H of
pyridine), 9.03–8.36 (m, 8H, Ar-H), 7.04 (s, 2H, Ar-H); MS
(m/z%) C25H13N9O4S2: 567.66 [M
+].
3.3.2.9. 2,20-pyridine-2,5-diylbis[6-(4-methoxyphenyl) imi-
dazo[2,1-b]-1,3,4-thiadiazole] 4(i). White solid crystals; yield
66%; mp: 320–322 C; IR (KBr, cm1): 2987, 1668, 1466,
683; 1HNMR (DMSOd6) d ppm: 9.13 (s, 2H of pyridine),
9.02 (s, 1H of pyridine), 8.96–7.99 (m, 7H, Ar-H), 7.21 (s,
3H, Ar-H), 3.80 (s, 6H, CH3O); MS (m/z%) C27H19N7O2S2:
538.69 [M + 1]+.
3.3.2.10. 2,20-pyridine-2,5-diylbis[6-(3-methoxyphenyl) imidazo
[2,1-b]-1,3,4-thiadiazole] 4(j). Yellow solid crystals; yield
57%; mp: 314–316 C; IR (KBr, cm1): 3005, 1656, 1447,
671; 1HNMR (DMSOd6) d ppm: 9.02 (bs, 3H of pyridine),
8.83–7.14 (m, 8H, Ar-H), 6.71 (s, 2H, Ar-H), 3.62 (s, 6H,
CH3O); MS (m/z%) C27H19N7O2S2: 537.80 [M
+].
3.3.2.11. 2,20-pyridine-2,5-diylbis[6-(3,4-dimethylphenyl) imi-
dazo [2,1-b]-1,3,4-thiadiazole] 4(k). White solid; yield 46%;
mp: 330–332 C; IR (KBr, cm1): 3015, 1665, 1469; 1HNMR
(DMSOd6) d ppm: 9.13 (s, 2H of pyridine), 8.94 (s, 1H of pyr-
idine), 8.63 (s, 3H, Ar-H), 7.81–7.15 (m, 5H, Ar-H), 2.72 (s,
3H, CH3); MS (m/z%) C29H23N7S2: 533.81 [M
+].
4. Conclusion
Irrefutably, we hereby report eleven synthesized derivatives
containing imidazo-thiadiazole moiety 4(a–k) which were
prosecuted for antibacterial activity against the standard drug
ampicillin and antifungal activity against amphotericin B as
the standard drug. Among the synthesized compounds, 4(a),
4(b), 4(f), 4(h) and 4(k) were found to be the most promising
candidates against B. pumillus, S. aureus, V. cholera, E. coli,
P. mirabilis, P. aeruginosa and C. albicans. Different substitu-
tions and structural diversity of the reported compounds were
found to play an eminent role in their biological proﬁling. The
% inhibition of all the compounds was determined by observ-
ing the zone of inhibition formed around the cup after 24 h of
incubation for antibacterial and 48 h for antifungal activities.
Keeping in mind of their biological diversity further develop-
ments on this area of subject are still under progress.
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